A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 498
- 试验地点
- 119
- 主要终点
- Number of Participants Who Experience One or More Adverse Events During Extended-Duration Use
研究概览
简要总结
The primary purpose of this study is to assess the efficacy and safety of the etonogestrel (ENG) contraceptive implant during participants' fourth and fifth years of use when used as the only method of contraception. The ENG implant is currently approved for a 3-year duration, and this study aims to confirm available evidence suggesting that the ENG implant remains highly effective when used up to 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- — 至 35 Years（Child, Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Not diagnosed with perimenopause or menopause.
- •Heterosexually active with a partner who is not known to be subfertile, sterilized, or infertile, and is seeking contraception for pregnancy.
- •Palpable intact ENG implant in the upper inner-arm for 36 months from the date of insertion at the time of enrollment, and has documentation of the insertion date (for example, Nexplanon user card or medical record completed on the date of insertion).
- •Does not desire a pregnancy within the 24 months after enrollment, is willing to continue use of the implant for an additional 24 months, and is not intending to use any other form of contraception (eg, condoms) from enrollment until after implant removal at 24 months post enrollment.
- •Good physical and mental health in the medical judgment of the investigator.
- •History of regular menstrual cycles of 21 to 35 days before the insertion of the ENG implant or before hormonal contraceptive use (which may have preceded the current implant use).
- •Able and willing to adhere to all required study procedures, including study visits and eDiary entries, and not planning to relocate during the study.
排除标准
- •Conceived a pregnancy during use of the current implant or a past contraceptive implant.
- •Known or suspected pregnancy at the time of screening or enrollment visit.
- •History of subfertility or infertility.
- •Breastfeeding.
- •Untreated gonorrhea, chlamydia, or trichomonas or symptomatic vaginitis/cervicitis.
- •Significantly abnormal cervical cytology (Pap) or pathology results either at screening or documented in the 36-month period prior to enrollment.
- •Current use of an intrauterine device/intrauterine system (IUD/IUS).
- •Presence of more than one ENG implant.
- •Use of daily/monthly hormonal contraceptives, sex steroids, or GnRH agonist/antagonist within 3 months prior to enrollment.
- •Use of injectable hormonal contraceptive with 3-month duration within 9 months prior to enrollment.
- •Use of injectable GnRH agonist with 3-month duration within 10 months prior to enrollment .
- •Use of medications that induce liver enzymes within 2 months prior to enrollment.
- •Untreated or unresolved vaginal bleeding or spotting attributable to underlying pathology in the 12 months before screening.
- •Frequent, prolonged, or excessive vaginal bleeding/spotting in the 12 months prior to screening which has not been evaluated to detect underlying pathology.
- •History of venous thromboembolism or arterial thromboembolism, transient ischemic attack, angina pectoris, or claudication.
- •Any condition associated with an increased risk of venous thromboembolism.
- •Uncontrolled or severe hypertension at screening visit.
- •Clinically significant liver disease, including active viral hepatitis or cirrhosis.
- •History of malignancy within 5 years before screening, except treated skin cancer.
- •History of sex steroid-influenced malignancies (eg, genital organs, breasts).
- •History or presence of liver tumors (benign or malignant).
- •Known allergy/sensitivity or contraindication to the ENG implant or lidocaine with epinephrine.
- •History of drug or alcohol abuse or dependence within 24 months prior to enrollment. Routine use of alcohol or marijuana that is not considered abuse or dependence is not exclusionary.
- •Use of an investigational drug within 2 months prior to enrollment. Long-term follow up of an investigational compound for COVID-19 is allowed 2 months after the last administered dose.
- •Staff or immediate family members of the investigational site or Sponsor directly involved with this study.
研究组 & 干预措施
ENG implant
Participants will have the ENG 68 mg implant inserted and in place for 36 months before enrollment. The ENG implant will remain in place for an additional 24 months.
干预措施: Radiopaque Etonogestrel (ENG) Implant (Combination Product)
结局指标
主要结局
Number of Participants Who Experience One or More Adverse Events During Extended-Duration Use
时间窗: Up to approximately 27 months
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Pregnancy Rate (Pearl Index) for At Risk Cycles During Extended-Duration Use
时间窗: Up to 24 months
The Pearl Index is expressed as the number of on-treatment pregnancies per 100 woman-years of exposure. An on-treatment pregnancy is defined as a confirmed pregnancy with an estimated date of conception 36 months to 60 months since the date of implant insertion. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "at risk" cycles for conception will be included in this Pearl Index calculation. An at risk cycle is defined as a cycle during which participants with ENG implant had affirmed heterosexual intercourse without the use of additional contraception.
Number of Participants Who Discontinue Treatment (Implant Removed) Due to an Adverse Event During Extended-Duration Use
时间窗: Up to approximately 24 months
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Pregnancy Rate (Pearl Index) for Alternative At Risk Cycles During Extended-Duration Use
时间窗: Up to 24 months
The Pearl Index is expressed as the number of on-treatment pregnancies per 100 woman-years of exposure. An on-treatment pregnancy is defined as a confirmed pregnancy conceived with an estimated date of conception 36 months to 60 months since the date of implant insertion. Exposure in 100 woman-years is equal to the number of cycles of use/1300, and one woman-year is defined as a period of 13 treatment cycles, each 28 days long. Only "alternative at risk" cycles will be included in this Pearl Index calculation. An alternative at risk cycle is defined as a cycle in which participants with ENG implant did not use additional contraception, but without the requirement for affirmed heterosexual intercourse.
次要结局
- Pregnancy Rate (Pearl Index) for At Risk Cycles During Year 5 of Implant Use(Up to 12 months)
- Pregnancy Rate (Pearl Index) for At Risk Cycles During Year 4 of Implant Use(Up to 12 months)
- Cumulative Pregnancy Rate During 5 Years of Implant Use(Up to 60 months (From 3 years prior to study entry to 2 years after study entry))
- Mean Length of Bleeding and/or Spotting Episodes During Extended-Duration Use as Assessed in 90-day Reference Periods(Up to 24 months)
- Percentage of Participants per 90-Day Reference Period with Normal Frequency Bleeding and/or Spotting During Extended-Duration Use(Up to 24 months)
- Pregnancy Rate (Pearl Index) for Alternative At Risk Cycles During 5 Years of Implant Use(Up to 60 months (From 3 years prior to study entry to 2 years after study entry))
- Percentage of Participants per 90-day Reference Period with Amenorrhea During Extended-Duration Use(Up to 24 months)
- Percentage of Participants per 90-Day Reference Period with Infrequent Bleeding and/or Spotting During Extended-Duration Use(Up to 24 months)
- Pregnancy Rate (Pearl Index) for At Risk Cycles During 5 Years of Implant Use(Up to 60 months (From 3 years prior to study entry to 2 years after study entry))
- Number of Spotting Days During Extended-Duration Use as Assessed in 90-day Reference Periods(Up to 24 months)
- Percentage of Participants per 90-Day Reference Period with Frequent Bleeding and/or Spotting During Extended-Duration Use(Up to 24 months)
- Cumulative Pregnancy Rate During 4 Years of Implant Use(Up to 48 months (From 3 years prior to study entry to 1 year after study entry))
- Number of Bleeding Days During Extended-Duration Use as Assessed in 90-day Reference Periods(Up to 24 months)
- Number of Bleeding and/or Spotting Days During Extended-Duration Use as Assessed in 90-day Reference Periods(Up to 24 months)
- Number of Complications Associated with Implant Removal(Up to 24 months)
- Percentage of Participants per 90-Day Reference Period with Prolonged Bleeding and/or Spotting During Extended-Duration Use(Up to 24 months)